Date: 2017-04-03
Type of
information: Presentation of results at a congress
phase: preclinical, 1
Announcement: presentation of results at the American Society of Clinical Oncology (ASCO) annual meeting, in Chicagoat the International conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
Company: Piramal Imaging (India) AC Immune (Switzerland)
Product: PI-2620
Action
mechanism:
- imaging agent. PI-2620 is a tau PET imaging tracer discovered in a research collaboration between Piramal Imaging and AC Immune. First–in-man clinical studies were performed at Molecular Neuroimaging, a division of Invicro, New Haven, Connecticut.
Disease: Alzheimer's disease, Progressive Supranuclear Palsy (PSP)
Therapeutic
area: Neurodegenerative diseases
Country:
Trial
details:
Latest
news:
- • On April 3, 2017, Piramal Imaging and AC Immune SA presented the pre-clinical profile and first clinical data
of the investigational next generation tau PET-imaging tracer PI-2620 at the International conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
(AD/PD) , in Vienna, Austria.
- PI-2620 is the result of a research collaboration between the two companies. First results of the ongoing clinical program confirmed the favorable potential of PI-2620. In contrast to first generation tau tracers, PI-2620 did not exhibit an increased tracer uptake in choroid plexus, striatum, amygdala or other regions of non-demented control subjects. In
Alzheimer’s disease subjects, however, the PI-2620 tau PET-scan showed a clear pattern of high uptake particularly in the lateral temporal and frontal lobes, consistent with the
expected tau pathology. Uptake in substantia nigra and globus pallidus of Progressive Supranuclear Palsy (PSP) subjects was strong.
- The pre-clinical characterization and first clinical data of PI-2620 were presented in two abstracts during the AD/PD 2017 meeting.
- 1) John Seibyl et al.: First in human characterization of PI-2620, a next generation PET tracer for assessing tau in Alzheimer’s disease and other tauopathies.
- 2) Andrew Stephens et al.: Characterization of novel PET tracers for the assessment of tau pathology in Alzheimer’s disease and other tauopathies.
Is
general: Yes
